PulseAugur
EN
LIVE 17:49:55
ENTITY Life Biosciences

Life Biosciences

PulseAugur coverage of Life Biosciences — every cluster mentioning Life Biosciences across labs, papers, and developer communities, ranked by signal.

Show in brief
Total · 30d
0
7 over 90d
Releases · 30d
0
0 over 90d
Papers · 30d
0
1 over 90d
TIER MIX · 90D
TOPICS
RECENT · PAGE 1/1 · 7 TOTAL
  1. TOOL · CL_98619 ·

    Longevity field's cellular reprogramming theory faces human trial reality check

    A groundbreaking human trial has begun for a gene therapy aimed at partially reprogramming older cells to a younger state, a development that could validate key theories in the longevity medicine field. This early-stage…

  2. TOOL · CL_94982 ·

    First Human Receives Cellular Rejuvenation Therapy in Landmark Trial

    A biotechnology startup, Life Biosciences, has initiated a clinical trial treating the first human with a cellular reprogramming therapy aimed at reversing aging. This therapy, which utilizes three Yamanaka factors to r…

  3. TOOL · CL_88397 ·

    Life Biosciences begins human trials for age-reversal drug

    Life Biosciences has initiated its first human trials for an experimental drug designed to reverse age-related conditions. The drug employs a "reprogramming" strategy to combat the effects of aging.

  4. TOOL · CL_88300 ·

    Life Biosciences trials nerve regeneration treatment for glaucoma

    Life Biosciences has dosed its first volunteer with an experimental treatment aimed at regenerating healthy eye nerves for glaucoma patients. This marks a significant advancement in the pursuit of reversing age-related …

  5. COMMENTARY · CL_87252 ·

    MIT Tech Review: Cell reprogramming for aging reversal and interoception research gain momentum

    MIT Technology Review's newsletter, The Download, highlights two emerging areas of scientific research: the "reprogramming" of cells to reverse aging and the study of interoception, the internal sense of bodily feelings…

  6. TOOL · CL_81787 ·

    Life BioSciences begins Phase 1 trial for optic neuropathy drug

    Life BioSciences has announced a significant milestone with the first patient dosed in a Phase 1 clinical trial for ER-100, an epigenetic restoration drug candidate. This drug targets optic neuropathies, a group of diso…

  7. RESEARCH · CL_80633 ·

    David Sinclair to test oral rejuvenation drug in XPrize competition

    Longevity scientist David Sinclair is preparing to test an oral drug mixture, code-named SL-100, for whole-body rejuvenation. This initiative is part of a $101 million XPrize competition aimed at restoring individuals t…